Literature DB >> 19935744

Direct renin inhibition and the kidney.

Norman K Hollenberg1.   

Abstract

Direct renin inhibition is a new means for blocking the renin-angiotensin system at the rate-limiting step of the cascade of events triggered by renin release--the interaction of renin with its physiological substrate angiotensinogen. The remarkable success of angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers in the management of cardiovascular and renal disease has led to great interest in the potential of direct renin inhibitors. This Review focuses on the evidence that suggests that direct renin inhibitors might block the renin-angiotensin system in the kidney more completely than either angiotensin-converting-enzyme inhibitors or angiotensin receptor blockers. The therapeutic implications of this evidence are also reviewed, as well as the possible mechanistic routes by which direct renin inhibition might exert its influence on the kidney.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19935744     DOI: 10.1038/nrneph.2009.201

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN: 1759-5061            Impact factor:   28.314


  31 in total

1.  Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.

Authors:  Suzanne Oparil; Steven A Yarows; Samir Patel; Hui Fang; Jack Zhang; Andrew Satlin
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

Review 2.  Implications of species difference for clinical investigation: studies on the renin-angiotensin system.

Authors:  N K Hollenberg
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

3.  Human prorenin has "gate and handle" regions for its non-proteolytic activation.

Authors:  Fumiaki Suzuki; Makoto Hayakawa; Tsutomu Nakagawa; Uddin Mohammad Nasir; Akio Ebihara; Atsushi Iwasawa; Yuichi Ishida; Yukio Nakamura; Kazuo Murakami
Journal:  J Biol Chem       Date:  2003-04-08       Impact factor: 5.157

4.  Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus.

Authors:  D M Wilson; J A Luetscher
Journal:  N Engl J Med       Date:  1990-10-18       Impact factor: 91.245

5.  Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Mathieu Ghadanfar; Nicole Weissbach; Zhihua Xiang; Juergen Armbrecht; Marc A Pfeffer
Journal:  Nephrol Dial Transplant       Date:  2009-01-14       Impact factor: 5.992

6.  Effects of blocking the angiotensin II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs.

Authors:  A I el Amrani; J Menard; M F Gonzales; J B Michel
Journal:  J Cardiovasc Pharmacol       Date:  1993-08       Impact factor: 3.105

7.  Aliskiren combined with losartan in type 2 diabetes and nephropathy.

Authors:  Hans-Henrik Parving; Frederik Persson; Julia B Lewis; Edmund J Lewis; Norman K Hollenberg
Journal:  N Engl J Med       Date:  2008-06-05       Impact factor: 91.245

Review 8.  The (pro)renin receptor: a new kid in town.

Authors:  Geneviève Nguyen
Journal:  Semin Nephrol       Date:  2007-09       Impact factor: 5.299

Review 9.  Renin inhibition: what are the clinical perspectives?

Authors:  Norman K Hollenberg
Journal:  Semin Nephrol       Date:  2007-09       Impact factor: 5.299

10.  Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms.

Authors:  Y Huang; S Wongamorntham; J Kasting; D McQuillan; R T Owens; L Yu; N A Noble; W Border
Journal:  Kidney Int       Date:  2006-01       Impact factor: 18.998

View more
  12 in total

Review 1.  Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.

Authors:  Robert C Stanton
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

2.  Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Authors:  Jan Wysocki; Minghao Ye; Ahmed M Khattab; Agnes Fogo; Aline Martin; Nicolae Valentin David; Yashpal Kanwar; Mark Osborn; Daniel Batlle
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

Review 3.  Direct renin inhibition in chronic kidney disease.

Authors:  Frederik Persson; Peter Rossing; Hans-Henrik Parving
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

4.  Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.

Authors:  Lanqi Jia; Robert D Simpson; Jing Yuan; Zhenrong Xu; Wei Zhao; Salvacion Cacatian; Colin M Tice; Joan Guo; Alexey Ishchenko; Suresh B Singh; Zhongren Wu; Brian M McKeever; Yuri Bukhtiyarov; Judith A Johnson; Christopher P Doe; Richard K Harrison; Gerard M McGeehan; Lawrence W Dillard; John J Baldwin; David A Claremon
Journal:  ACS Med Chem Lett       Date:  2011-08-09       Impact factor: 4.345

5.  Inhibition of renin activity slows down the progression of HIV-associated nephropathy.

Authors:  Dileep Kumar; Andrei Plagov; Iti Yadav; Deepti D Torri; Swapna Sayeneni; Ankita Sagar; Partab Rai; Madhuri Adabala; Rivka Lederman; Nirupama Chandel; Guohua Ding; Ashwani Malhotra; Pravin C Singhal
Journal:  Am J Physiol Renal Physiol       Date:  2012-06-20

Review 6.  Application of direct renin inhibition to chronic kidney disease.

Authors:  Christian W Mende
Journal:  Cardiovasc Drugs Ther       Date:  2010-04       Impact factor: 3.727

7.  Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy.

Authors:  Frederik Persson; Julia B Lewis; Edmund J Lewis; Peter Rossing; Norman K Hollenberg; Hans-Henrik Parving
Journal:  Diabetes Care       Date:  2010-08-06       Impact factor: 17.152

Review 8.  Inhibition of RAS in diabetic nephropathy.

Authors:  Rabi Yacoub; Kirk N Campbell
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-04-15

9.  Effects of aliskiren-based therapy on ambulatory blood pressure profile, central hemodynamics, and arterial stiffness in nondiabetic mild to moderate hypertensive patients.

Authors:  Tomohiko Kanaoka; Kouichi Tamura; Masato Ohsawa; Hiromichi Wakui; Akinobu Maeda; Toru Dejima; Kengo Azushima; Sona Haku; Hiroshi Mitsuhashi; Mai Yanagi; Jin Oshikawa; Kazushi Uneda; Kazutaka Aoki; Tetsuya Fujikawa; Yoshiyuki Toya; Kazuaki Uchino; Satoshi Umemura
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-05-03       Impact factor: 3.738

Review 10.  Direct renin inhibition--a promising strategy for renal protection?

Authors:  Sławomir Lizakowski; Leszek Tylicki; Bolesław Rutkowski
Journal:  Med Sci Monit       Date:  2013-06-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.